Investigational drug · Phase 2
Linrodostat
Also called: BMS-986205
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
24
Any phase or sponsor naming "Linrodostat"
First trial start
2018
May 30, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Linrodostat", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Cancer
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Linrodostat" as an intervention, largest first.
- An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have SpreadPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT02658890 · 627 participants · Start Apr 14, 2016 · Primary completion Oct 26, 2021
Drug: BMS-986205; Nivolumab and 1 more · For: Advanced Cancer; Melanoma; Non-Small Cell Lung Cancer
Sites: Tucson, Arizona; La Jolla, California; Tampa, Florida · 47 sites in all
- An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung CancerPivotal-lookingTerminated
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT02750514 · 295 participants · Start May 9, 2016 · Primary completion Jan 29, 2020
Drug: Nivolumab; Dasatinib and 3 more · For: Advanced Cancer
Sites: Duarte, California; Los Angeles, California; Newport Beach, California · 50 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT03459222 · 229 participants · Start May 30, 2018 · Primary completion Feb 19, 2025
Drug: Relatlimab; Nivolumab and 2 more · For: Advanced Cancer
Sites: Duarte, California; Aurora, Colorado; Baltimore, Maryland · 22 sites in all
- A Study to Test Combination Treatments in Participants With Advanced Gastric CancerPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT02935634 · 190 participants · Start Nov 29, 2016 · Primary completion May 11, 2022
Drug: Nivolumab; Ipilimumab and 3 more · For: Advanced Gastric Cancer
Sites: Phoenix, Arizona; Duarte, California; Aurora, Colorado · 35 sites in all
- A Study to Test Combination Treatments in People With Advanced Renal Cell CarcinomaPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT02996110 · 182 participants · Start Feb 2, 2017 · Primary completion Nov 23, 2021
Drug: Nivolumab; Ipilimumab and 3 more · For: Advanced Cancer
Sites: New Haven, Connecticut; Tampa, Florida; Augusta, Georgia · 32 sites in all
- A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the BladderPivotal-lookingTerminated
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT03519256 · 142 participants · Start Aug 2, 2018 · Primary completion Aug 22, 2022
Drug: Nivolumab; BCG and 1 more · For: Urinary Bladder Neoplasms
Sites: Los Angeles, California; Riverside, California; San Francisco, California · 88 sites in all
Thomas Jefferson UniversityAcademic, hospital or other
NCT03854032 · 65 participants · Start Apr 9, 2019 · Primary completion Feb 10, 2022
Drug: Nivolumab; IDO1 Inhibitor BMS-986205 · For: Lip; Oral Cavity Squamous Cell Carcinoma; Pharynx and 2 more
Sites: Columbus, Ohio; Philadelphia, Pennsylvania
- A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy SubjectsCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT03346837 · 53 participants · Start Nov 22, 2017 · Primary completion Dec 20, 2017
Drug: BMS-986205; Itraconazole and 1 more · For: Malignancies Multiple
Sites: Austin, Texas
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT03362411 · 40 participants · Start Nov 9, 2017 · Primary completion Feb 1, 2018
Drug: BMS-986205 · For: Healthy Volunteers
Sites: Austin, Texas
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT03312426 · 32 participants · Start Oct 9, 2017 · Primary completion Nov 22, 2017
Drug: BMS-986205 · For: Healthy Volunteers
Sites: Austin, Texas
Newest research
PubMed records naming it or its code names, newest first.
- Heterocyclic scaffolds targeting IDO1: progress in medicinal chemistry and clinical development.
Kumar A, Sharma V, Patel R, et al. · Future Med Chem 2026
- Bioengineered Stroma-Camouflaged Nanovesicles Disrupt the IDO1/CD276 Immunosuppressive Circuit to Reinvigorate Antitumor Immunity.
Zhang Z, Luo J, Zhang M, et al. · Adv Sci (Weinh) 2026
- Phase I Evaluation of Patients with Newly Diagnosed Glioblastoma Treated with Radiation, Nivolumab, and IDO1 Enzyme Inhibitor BMS-986205.
Lukas RV, Zhai L, Lauing KL, et al. · Clin Cancer Res 2026
- Artemether and Euphorbia factor L9 suppress kynurenine production through distinct effects on tryptophan metabolism.
Capatina AL, Czechowski T, Plunkett-Jones C, et al. · Biochem J 2026
- Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Survival Outcomes in Head and Neck Squamous Cell Carcinoma Receiving Neoadjuvant Immunotherapy.
Llerena P, Kaki PC, Nunes K, et al. · Cancer Med 2026
- Fast Real-Time Assessment of Combination Therapies in Immuno-ONcology in patients with advanced non-small-cell lung cancer (FRACTION-Lung).
He K, Forde PM, Govindan R, et al. · ESMO Open 2026
Also in development for Advanced Cancer
- ObrixtamigBI 764532Phase 36 trials
Boehringer Ingelheim · Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology
- EzabenlimabBI 754091Phase 32 trials
Boehringer Ingelheim · Advanced Cancer, Neoplasm Metastasis, Advanced Tumors
- ALK201Phase 22 trials
Shanghai Allink Biotherapeutics Co., Ltd. · NSCLC (Advanced Non-small Cell Lung Cancer), Advanced Cancer, Advanced Solid Tumors
- CVM-1118TRX-818Phase 22 trials
TaiRx, Inc. · Hepatocellular Carcinoma, Advanced Cancer, Neuroendocrine Tumors
- KB707Phase 22 trials
Krystal Biotech, Inc. · Cancer, Melanoma Stage III, Melanoma Stage IV
- LY188011Phase 22 trials
Eli Lilly · Neoplasms, Child, Adolescent
- Personalized Neoantigen Peptide VaccinePhase 22 trials
Seqker Biosciences, Inc. · Solid Tumors, Advanced Cancer, Recurrent Cancer
- TST001Phase 22 trials
Transcenta Therapeutics (Hangzhou) Co., Ltd. · Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Bristol Myers Squibb.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.